 |
 |

Intravitreal Triamcinolone in Diabetic Macular Edema
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
We read with great interest the article by Jonas et al1 and wish to highlight a number of points.
According to their Figure 1, the number of eyes at follow-up is reduced significantly from 53 to 8 eyes, which implies that 45 cases are unavailable for assessment at 9 months. This could clearly influence the conclusions of the study.
We also question the grading of macular edema based on the intensity of stain from standard nonstereoscopic photographs, which is highly subjective and does not allow for the potential for significant variability in interpreted hyperfluorescence. With respect to the grading system, the use of a single examiner precludes assessment of interobserver variability. Also, the classification of macular edema from 0 to 6 is abandoned in favor of broader categories, ie, 0 to 2, 3 to 4, and 5 to 6, for statistical analysis.
In their Figure 2, the total number of . . . [Full Text of this Article] AUTHOR INFORMATION
Sher Aslam, MRCOphth;
Nabeel Malik, FRCOphth;
Nigel Davies, PhD, FRCOphth
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
RELATED ARTICLES
Intravitreal Triamcinolone in Diabetic Macular EdemaReply
Jost B. Jonas, Peter Martus, Robert F. Degenring, Ingrid Kreissig, and Imren Akkoyun
Arch Ophthalmol. 2006;124(10):1507.
EXTRACT
| FULL TEXT
Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jost B. Jonas, Peter Martus, Robert F. Degenring, Ingrid Kreissig, and Imren Akkoyun
Arch Ophthalmol. 2005;123(10):1338-1343.
ABSTRACT
| FULL TEXT
|